Strides Pharma Stock Surges 10% on Strong Q3 Results, US Outlook Maintained

• Strides Pharma shares jumped 10% following robust December quarter results.
• The company reported a net profit of ₹202 crore, a significant increase from ₹88 crore year-on-year.
• Revenue grew 3.6% to ₹1,194.6 crore, with EBITDA up 12.2% to ₹235.8 crore.
• Margins expanded, with EBITDA margins at 19.7% and gross margins at 61.2%.
• Strides Pharma reiterated its US business revenue outlook of $400 million by FY28 and appointed Peter Hardwick as North America CEO.

Why It Matters: Strides Pharma's strong Q3 performance, expanded margins, and maintained US outlook fueled a 10% stock surge.